Conclusions
thrombosis, thromboembolic
THROMBOSIS, EVENTS, THROMBOEMBOLIC EVENT
In this phase 2 randomized clinical trial, postbariatric thrombosis prophylaxis with 10 mg/d of rivaroxaban was associated with a very low incidence of thromboembolic events irrespective of treatment duration. The number of safety events was higher in the long prophylaxis group compared with the short prophylaxis group, but this difference was not statistically significant. Our data suggest that thromboembolic prophylaxis with 10 mg of rivaroxaban for 7 days after bariatric surgery is efficacious and safe. A larger prospective trial in patients undergoing bariatric surgery comparing thromboembolic prophylaxis with short-term DOAC and extended LMWH treatment would be valuable to confirm the results of this study and to guide future prophylactic treatment.